Kennedy, now serving as health secretary, disclosed in June 2025 that he traveled to the Caribbean for unproven stem cell injections to treat a throat condition. The admission alarmed researchers who feared it signaled a hands-off approach toward a sprawling domestic industry that markets unproven cellular therapies for everything from joint pain to neurological disease.
Two Fronts of Enforcement
Instead of retreating, the Food and Drug Administration has pressed forward on two major fronts, according to UC Davis cell biology professor Paul Knoepfler, who tracks the regenerative medicine field. The agency has maintained its regulatory posture against clinics operating outside approved pathways while also advancing science-based frameworks for legitimate cell therapies.
The FDA’s stance stands out in an administration critics have accused of injecting ideology into health policy decisions. Stem cell oversight has historically been one of the agency’s most contested domains, pitting patient demand against the requirement for rigorous clinical evidence.
A History of Warnings and Raids
The FDA began intensifying enforcement against unproven stem cell clinics during the first Trump administration, when then-Commissioner Scott Gottlieb made the issue a priority. The agency sent warning letters to dozens of clinics, including a high-profile 2018 case against Florida-based U.S. Stem Cell Clinic after patients suffered severe complications, including blindness.
That enforcement continued under the Biden administration, with the FDA winning court rulings affirming its authority to regulate stem cell products as drugs requiring approval. A pivotal 2020 federal court decision against U.S. Stem Cell Clinic established that clinics cannot bypass the drug approval process simply by extracting and reinjecting a patient’s own cells.
By 2025, the unproven stem cell industry had grown into a sprawling marketplace, with an estimated hundreds of clinics operating across the United States. Many market autologous fat-derived stem cell injections for conditions lacking clinical evidence, charging patients thousands of dollars per treatment.
Kennedy’s Caribbean Treatment Raises Questions
Kennedy’s revelation that he sought stem cell therapy abroad highlighted the appeal of these treatments among public figures, even as regulators warn against them. The health secretary’s throat condition has not been publicly detailed, and the specific clinic he visited has not been disclosed.
His personal experience created an apparent tension: the nation’s top health official pursuing a treatment his own department’s regulators have flagged as potentially dangerous. Patient advocacy groups and academic researchers expressed concern that Kennedy’s platform could lend credibility to clinics the FDA has spent years trying to rein in.
Stem cell tourism, the practice of traveling abroad for unregulated therapies, has been a persistent concern for the FDA and the Centers for Disease Control and Prevention. Cases of patients returning with infections, tumors, or other complications have been documented in medical literature for over a decade.
Science-Based Regulation Holds
What makes the FDA’s recent enforcement notable is the broader political context. The Trump administration has moved aggressively to reshape health agencies, restructuring leadership and questioning established scientific consensus on issues ranging from vaccines to chronic disease. Against that backdrop, continued stem cell enforcement represents a pocket of continuity.
Knoepfler, who writes the Lab Dish column for STAT covering regenerative medicine, noted that the agency’s science-based approach has survived despite ideological pressures elsewhere in the Department of Health and Human Services. The FDA’s Center for Biologics Evaluation and Research, which oversees cell therapies, has maintained its evidentiary standards for clinical trials and product approval.
Legitimate regenerative medicine research continues to advance, with approved cell therapies for certain blood cancers and ongoing trials for conditions including spinal cord injury and Parkinson’s disease. The distinction between approved therapies and the unproven treatments sold at many clinics remains central to FDA messaging.
What Happens Next
The FDA’s continued enforcement suggests the unproven stem cell clinic industry will face ongoing scrutiny regardless of Kennedy’s personal views. Watch for additional warning letters, court filings, and potential guidance updates in coming months as the agency clarifies its expectations for clinics offering cell-based treatments.
Kennedy’s role creates an unusual dynamic to monitor. If he publicly advocates for broader access to unproven stem cell therapies, it could pressure the FDA to soften its stance. For now, the agency appears committed to its evidence-based framework, but the political environment remains volatile.
Patients considering stem cell treatments should verify whether a therapy has FDA approval or is part of a registered clinical trial. The agency maintains a public database of approved cellular and gene therapy products, and clinical trials can be searched through the federal registry at ClinicalTrials.gov.
— Aisha Mensah, health desk, AXO News